사전정보공개
지원내역 담당자 세부지원내역 기준 고유번호 기타참고사항
In vitro Efficacy Dr. 강종순, 전화 : 043-240-6524, kanjon@kribb.re.kr Cancer      
Immune      
기타      
In vivo Efficacy Dr. 강종순, 전화 : 043-240-6524, kanjon@kribb.re.kr Cancer      
Rheumatoid Arthritis      
Diabetes      
Obesity      
Osteoporosis      
Dermatitis      
Gastric Ulcer      
Analysis Dr. 강종순, 전화 : 043-240-6524, kanjon@kribb.re.kr In vivo sample      
Etc.      
In vitro ADME Dr. 오수진, 전화 : 043-240-6525, diatree @kribb.re.kr Solution properties      
Permeability      
Drug metabolism      
Drug metabolism      
Drug metabolism      
Drug-drug interaction      
In vivo PK Dr. 오수진, 전화 : 043-240-6525, diatree @kribb.re.kr In vivo PK      
Bioanalysis Dr. 오수진, 전화 : 043-240-6525, diatree @kribb.re.kr Bioanalysis      
LMO 환경위해성평가 Dr. 김창기 , 전화 : 043-240-6543, cgkim@kribb.re.kr LMO 환경위해성평가      
LMO 유전자분석 Dr. 정순천 , 전화 : 043-240-6540, scjeong@kribb.re.kr LMO 유전자분석      
In vitro Efficacy Dr. 강종순, 전화 : 043-240-6524, kanjon@kribb.re.kr Cancer SRB assay (원하는 세포주, 1,000 종 이상의 세포주 보유) GI50 BEC0001  
Cell cycle analysis Cell cycle distribution BEC0002  
Cell attachment (Matrigel, Collagen, Fibronectin, Vitronectin, Laminin, HUVEC, C166) IC50, changes vs. vehicle group BEC0003  
Migration, transwell IC50, changes vs. vehicle group BEC0004  
Migration, wound healing Photo, changes vs. vehicle group BEC0005  
Tube formation Photo, changes vs. vehicle group BEC0006  
Immune Lymphocyte proliferation IC50, changes vs. vehicle group BEC0007  
Mixed lymphocyte reaction IC50, changes vs. vehicle group BEC0008  
Cytokine production IC50, changes vs. vehicle group BEC0009  
Cytokine mRNA expression (Gel, Real-time PCR) IC50, changes vs. vehicle group BEC0010  
Phagocytic activity IC50, changes vs. vehicle group BEC0011  
NK cell cytotoxicity IC50, changes vs. vehicle group BEC0012  
Subset analysis, FACS % of total cells BEC0013  
기타 기타 세포시험 및 분석   BEC0014  
In vivo Efficacy Dr. 강종순, 전화 : 043-240-6524, kanjon@kribb.re.kr Cancer Tumor, Syngeneic Body weight, Tumor size, Tumor weight BEC0015  
Tumor, Matrigel, Angiogenesis Body weight, Amount of blood in matrigel BEC0016  
Tumor, Syngeneic, Metastasis Body weight, # of metastatic nodule BEC0017  
Tumor, Xenograft Body weight, Tumor size, Tumor weight BEC0018  
Tumor, Xenograft, Orthotopic Body weight, Tumor weight BEC0019  
Rheumatoid Arthritis Arthritis, Carrageenan Body weight, Paw volume BEC0020  
Arthritis, Zymosan Body weight, PLN weight BEC0021  
Arthritis, Adjuvant Body weight, Paw volume BEC0022  
Arthritis, Collagen Body weight, Clinical score BEC0023  
Arthritis, Collagen (mAb) Body weight, Clinical score BEC0024  
Diabetes Diabetes, Oral glucose tolerance Blood glucose BEC0025  
Diabetes, Streptozotocin Body weight, Blood glucose BEC0026  
Diabetes, NOD Body weight, Blood glucose BEC0027  
Diabetes, ob/ob Body weight, Blood glucose BEC0028  
Diabetes, db/db Body weight, Blood glucose BEC0029  
Diabetes, KKAy Body weight, Blood glucose BEC0030  
Obesity Obesity, High-fat dient-induced Body weight BEC0031  
Obesity, Food efficiency Body weight/Food intake BEC0032  
Osteoporosis Osteoporosis, Ovariectomy Body weight, Uterine weight, BMD BEC0033  
Dermatitis Dermatitis, Phorbol Ester Changes in ear thickness BEC0034  
Dermatitis, DNCB Changes in ear thickness BEC0035  
Dermatitis, Oxazolone Changes in ear thickness BEC0036  
Gastric Ulcer Gastric Ulcer, Ethanol Ulcer area BEC0037  
Gastric Ulcer, Aspirin Ulcer area BEC0038  
Gastric Ulcer, Indomethacine Ulcer area BEC0039  
Gastric Ulcer, Acetic acid Ulcer area BEC0040  
Gastric Ulcer, Water immersion-resistant stress Ulcer area BEC0041  
Analysis Dr. 강종순, 전화 : 043-240-6524, kanjon@kribb.re.kr In vivo sample Bio-Plex cytokine array, Mouse, 23-Plex Plasma conc. of cytokines BEC0042  
Bio-Plex cytokine array, Mouse, 9-Plex Plasma conc. of cytokines BEC0043  
Bio-Plex diabetes array, Mouse, 8-Plex Plasma conc. of proteins related to diabetes BEC0044  
HbA1c Percentage of HbA1c in blood BEC0045  
Blood ketone Plasma conc. of ketone BEC0046  
In vitro ADME Dr. 오수진, 전화 : 043-240-6525, diatree @kribb.re.kr Solution properties Aqueous solubility (PBS, pH 7.4) Concentration of test compound BEC0047  
Protein binding (plasma, human) % Fub BEC0048  
Protein binding (plasma, dog, Beagle) % Fub BEC0049  
Protein binding (plasma, rat, Sprague-Dawley) % Fub BEC0050  
Protein binding (plasma, mouse) % Fub BEC0051  
Chemical stability (PBS, pH 7.4) % remaining BEC0052  
Permeability PAMPA Papp value BEC0053  
A-B permeability (Caco-2, pH 6.5/7.4) Papp value BEC0054  
A-B permeability (Caco-2, pH 7.4/7.4) Papp value BEC0055  
A-B permeability (Caco-2, pH 7.4/7.4 + verapamil) Papp value BEC0056  
B-A permeability (Caco-2, pH 6.5/7.4) Papp value BEC0057  
B-A permeability (Caco-2, pH 7.4/7.4) Papp value BEC0058  
B-A permeability (Caco-2, pH 7.4/7.4 + verapamil) Papp value BEC0059  
P-gp inhibition (Caco-2, digoxin substrate) Papp value BEC0060  
Drug metabolism Metabolic stability (liver microsomes, human) % remaining BEC0061  
Metabolic stability (liver microsomes, dog, Beagle) % remaining BEC0062  
Metabolic stability (liver microsomes, rat, Sprague-Dawley) % remaining BEC0063  
Metabolic stability (liver microsomes, mouse, CD-1) % remaining BEC0064  
Metabolic stability (liver S9, human) % remaining BEC0065  
Metabolic stability (liver S9, dog, Beagle) % remaining BEC0066  
Metabolic stability (liver S9, rat, Sprague-Dawley) % remaining BEC0067  
Metabolic stability (liver S9, mouse, CD-1) % remaining BEC0068  
Intrinsic clearance (liver microsomes, human) t1/2, CLint BEC0069  
Intrinsic clearance (liver microsomes, dog, Beagle) t1/2, CLint BEC0070  
Intrinsic clearance (liver microsomes, rat, Sprague-Dawley) t1/2, CLint BEC0071  
Intrinsic clearance (liver microsomes, mouse) t1/2, CLint BEC0072  
Drug metabolism Intrinsic clearance (liver S9, human) t1/2, CLint BEC0073  
Intrinsic clearance (liver S9, dog, Beagle) t1/2, CLint BEC0074  
Intrinsic clearance (liver S9, rat, Sprague-Dawley) t1/2, CLint BEC0075  
Intrinsic clearance (liver S9, mouse) t1/2, CLint BEC0076  
Blood stability (rat, Sprague-Dawley) % remaining BEC0077  
Blood stability (mouse, CD-1) % remaining BEC0078  
Half-life (blood, rat, Sprague-Dawley) t1/2 BEC0079  
Half-life (blood, mouse, CD-1) t1/2 BEC0080  
Serum or Plasma stability (human) % remaining BEC0081  
Serum or Plasma stability (dog, Beagle) % remaining BEC0082  
Serum or Plasma stability (rat, Sprague-Dawley) % remaining BEC0083  
Serum or Plasma stability (mouse, CD-1) % remaining BEC0084  
Drug metabolism Half-life (serum or plasma, human) t1/2 BEC0085  
Half-life (serum or plasma, dog, Beagle) t1/2 BEC0086  
Half-life (serum or plasma, rat, Sprague-Dawley) t1/2 BEC0087  
Half-life (serum or plasma, mouse, CD-1) t1/2 BEC0088  
Metabolite screen (liver microsomes, human) parent and formed metabolite(s) BEC0089  
Glucuronidation (liver microsomes, human) % remaining BEC0090  
Intrinsic clearacne, glucuronidation (liver microsomes, human) t1/2, CLint BEC0091  
Reaction phenotyping (liver microsomes, chemical inhibitor) % comsumed BEC0092  
Reaction phenotyping (recombinant CYPs) % turn over, % of total metabolism in human liver BEC0093  
Drug-drug interaction CYP2C19 inhibition (HLM, S-mephenytoin substrate) % inhibiton of control BEC0094  
CYP2D6 inhibition (HLM, dextromethorphan substrate) % inhibiton of control BEC0095  
CYP3A inhibition (HLM, midazolam substrate) % inhibiton of control BEC0096  
CYP3A inhibition (HLM, testosterone substrate) % inhibiton of control BEC0097  
CYP1A inhibition (HLM, phenacetin substrate) % inhibiton of control BEC0098  
CYP2C9 inhibition (HLM, tolbutamide substrate) % inhibiton of control BEC0099  
CYP2C19 inhibition (HLM, S-mephenytoin substrate) IC50 BEC0100  
CYP2D6 inhibition (HLM, dextromethorphan substrate) IC50 BEC0101  
CYP3A inhibition (HLM, midazolam substrate) IC50 BEC0102  
CYP3A inhibition (HLM, testosterone substrate) IC50 BEC0103  
CYP1A inhibition (HLM, phenacetin substrate) IC50 BEC0104  
CYP2C9 inhibition (HLM, tolbutamide substrate) IC50 BEC0105  
Cocktail CYP Inhibition (human liver microsomes) IC50 BEC0106  
In vivo PK Dr. 오수진, 전화 : 043-240-6525, diatree @kribb.re.kr In vivo PK PK in-life (rat, cannulated, IV) Plasma conc. of test compound BEC0107  
PK in-life (rat, cannulated , PO) Plasma conc. of test compound BEC0108  
PK in-life (mouse, IV, serial sampling) Plasma conc. of test compound BEC0109  
PK in-life (mouse, PO, serial sampling) Plasma conc. of test compound BEC0110  
Bioanalysis Dr. 오수진, 전화 : 043-240-6525, diatree @kribb.re.kr Bioanalysis LC-MS/MS optimization(method development) MRM, LC condition BEC0111  
Linearity 7~10 calibration curve BEC0112  
Recovery 0, 10, 100, 1000 ng/ml spiked tissue and tissue extract BEC0113  
MS/MS various scan mode BEC0114  
Quantitative bioanalysis (including sample preparation) Concentration of test compound BEC0115  
Metabolite screen (plasma, animal)_Semi-quantitative and Qualificative analysis parent and formed metabolite(s) BEC0116  
LMO 위해성평가 Dr. 김창기 , 전화 : 043-240-6543, cgkim@kribb.re.kr LMO 환경위해성평가 격리온실 재배 관리   BEC0117  
격리포장 재배 관리   BEC0118  
토양미생물군집구조 분석   BEC0119  
절지동물 군집 모니터링   BEC0120  
종자 발아 및 활력 분석   BEC0121
화분 발아 및 활력 분석   BEC0122
농업형질 평가   BEC0123  
LM 작물의 경쟁력 변화 분석   BEC0124  
LMO 유전자분석 Dr. 정순천 , 전화 : 043-240-6540, scjeong@kribb.re.kr LMO 유전분석 도입유전자의 삽입 여부 BEC0125  
도입유전자 위치 분석 BEC0126  
도입유전자 수 분석 BEC0127  
LMO 검출 kit 제작 BEC0128  
도입유전자의 비의도적 삽입 분석 BEC0129  
도입유전자의 비의도적 발현 분석 BEC0130